Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06233461
Other study ID # TAK-279-CD-2001
Secondary ID 2023-506704-14
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 5, 2024
Est. completion date July 23, 2027

Study information

Verified date June 2024
Source Takeda
Contact Takeda Contact
Phone +1-877-825-3327
Email medinfoUS@takeda.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.t


Description:

The drug being tested in this study is TAK-279. TAK-279 is being tested to treat participants with moderately to severely active Crohn's disease. The study will look at the efficacy and safety of TAK-279. The study will enroll approximately 268 patients. During the Induction Period participants will be randomly assigned to one of the following treatment groups in a ratio of 1:1:1:1 to receive TAK-279 or placebo which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need): 1. TAK-279 Dose 1 2. TAK-279 Dose 2 3. TAK-279 Dose 3 4. Placebo This multi-center trial will be conducted globally. The overall study duration is approximately 60 weeks including a 4-week safety follow-up period.


Recruitment information / eligibility

Status Recruiting
Enrollment 268
Est. completion date July 23, 2027
Est. primary completion date September 18, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. 2. Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI. 3. Participants must have had an inadequate response to, loss of response to, or intolerance to at least one conventional or biologic therapy for CD. 4. Participants must meet the contraception recommendations. Exclusion Criteria: 1. Participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, and/or ulcerative colitis. 2. Have complications of CD that might require surgery during the study. 3. Participants with a current ostomy. 4. Participants who have failed 3 or more classes of advanced therapies.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TAK-279
TAK-279 capsules.
Placebo
TAK-279 placebo-matching capsules.

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Nepean Clinical School Kingswood New South Wales
Australia Western Health/Footscray Hospital Melbourne Victoria
Australia Concord Repatriation General Hospital Sydney New South Wales
Belgium Hopital Universitaire de Bruxelles/ Academisch Ziekenhuis Burssel Brussels Anderlecht / Region Capitale De Bruxelles/ Brussel
Belgium CHU Saint-Pierre - Porte de Hal Bruxelles
Belgium Algemeen Ziekenhuis Maria Middelares Gent
Belgium Universitair Ziekenhuis Leuven Leuven
Belgium Universitair Ziekenhuis Leuven Leuven
Belgium Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman Liege
Canada Heritage Medical Research Clinic - University Of Calgary Calgary Alberta
Canada Nova Scotia Health Authority - Queen Elizabeth II Heath Sciences Centre Halifax Nova Scotia
Canada London Health Sciences Centre - University Hospital London Ontario
Canada London Health Sciences Centre - Victoria Hospital London Ontario
Canada Centre Hospitalier de l'Universite de Montreal Montreal Quebec
Canada Fraser Clinical Trials New Westminster British Columbia
Canada Mount Sinai Hospital Toronto Ontario
Canada Toronto Immune and Digestive Health Institute (TIDHI) Toronto Ontario
Canada GI Research Institute (G.I.R.I.) Vancouver British Columbia
China The Second Xiangya Hospital of Central South University Changsha Hunan
China Chongqing General Hospital Chongqing Chongqing Sheng
China Nanfang Hospital of Southern Medical University Guangzhou Guangdong
China Sun Yat-sen University (SYSU) - The First Affiliated Hospital Guangzhou Guangdong
China Sun Yat-sen University (SYSU) - The First Affiliated Hospital Guangzhou Guangdong
China Sun Yat-sen University - The Sixth Affiliated Hospital (Guangdong Gastrointestinal Hospital) Guangzhou Guangdong
China The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang
China Zhejiang University School of Medicine - Sir Run Run Shaw Hospital (SRRSH) Hangzhou Zhejiang
China Shanghai Jiao Tong University School of Medicine - Ruijing hospital Shanghai Shanghai
China Shanghai Pudong New District Zhoupu Hospital Shanghai
China Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine Shanghai Shanghai
China China Medical University (CMU) - First Affiliated Hospital Shenyang Liaoning Sheng
China China Medical University (CMU) - Shengjing Hospital (The Second Affiliated Hospital) - Huaxiang Campus Shenyang Liaoning Sheng
China Zhongshan Hospital Xiamen University Xiamen Fujian
China The First Affiliated Hospital of Zhejiang Chinese Medical University Zhejiang Zhejiang
Czechia Hepato-Gastroenterologie HK, s.r.o. Hradec Kralove
Czechia Fakultni Nemocnice Ostrava (FNO) Ostrava-Poruba
Czechia Thomayerova Nemocnice (TN) - I. Interni Klinika FTNsP/IPVZ Prague
Czechia Endogastro Praha s.r.o Praha
Czechia Axon Clinical s.r.o. Praha 5
Czechia IBD Clinical and Research centre Praha 9
Denmark Aalborg Hospital Aalborg
Denmark Bispebjerg Hospital, University of Copenhagen Copenhagen Nv
Denmark Sydvestjysk Region/Esbjerg Hospital Esbjerg
Denmark Hillerod Hospital, Hilleroed Sygehus Hillerod
Denmark Hvidovre Hospital Medicinsk Gastroenterologisk Afdeling Hvidovre
Denmark Hvidovre Hospital Medicinsk Gastroenterologisk Afdeling Hvidovre
Denmark Region Sjaelland Sygehus Nord, Koge Sygehus Koge
Denmark Odense Universitetshospital (OUH) (Odense University Hospital) Odense Syddanmark
France Centre Hospital Regional Et Universitaire De Tours (Chru Tours) - Houpital Trousseau Chambray-les-Tours
France CHU De Clermont Ferrand - Hopital Estaing Clermont-Ferrand
France Centre Hospitalier Universitaire de Montpellier - Hopital Saint-Eloi Montpellier
France Institut des MICI, Groupe Hospitalier Prive Ambroise Pare-Hartmann Neuilly Sur Seine
France Hopital l'Archet 2 Nice Cedex 3
France Hopital Saint Antoine Paris
France Hopital Nord Chu Saint-Etienne Saint Etienne
France Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil Toulouse
France Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil Toulouse cedex 09
France Centre Hospitalier Regional Universitaire de Nancy ¿ Hopital Brabois Vandoeuvre les Nancy
Germany Agaplesion Markus Krankenhaus Frankfurt Am Main
Germany Hamburger Forschungsinstitut Fuer Chronisch Entzuendliche Darmerkrankungen (HaFCED e.K.) Hamburg
Germany Medizinische Hochschule Hannover, Hannover Medical School Hannover
Germany Praxis fur Gastroenterologie Heidelberg
Germany Universitaetsklinikum Schleswig-Holstein, UKSH-Campus Kiel Kiel
Germany Medius Klinik Nuertingen, St. Marien- und St. Annastiftskrankenhaus Ludwigshafen
Germany Universitaetsklinikum Mannheim GmbH Mannheim
Germany Universitaetsklinikum Tuebingen Tuebingen
Germany University Hospital Of Ulm, Universitatsklinikum Ulm Ulm
Greece Evaggelismos Hospital (Evangelismos Hospital)-University of Athens Athens Attiki
Greece G.N.A. Gennimatas Athens
Greece Sotiria General Hospital of Athens Athens
Greece University of Athens School of Medicine, Alexandra General Hospital Athens Attiki
Greece University Hospital of Heraklion Heraklion Crete
Greece University General Hospital of Patras Patras Achaia
Hungary Clinexpert Budapest
Hungary Pannonia Maganorvosi Centrum Kft. Budapest
Hungary Semmelweis Egyetem Budapest
Hungary Synexus DRS Budapest Budapest
Italy IRCCS A.O.U. Policlinico S. Orsola - Malpighi Bologna
Italy Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena - Clinica Mangiagalli Milano
Italy Ospedale San Raffaele (HSR) Instituto Scientifico Universitario San Raffaele Milano
Italy Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello Palermo
Italy A. Gemelli University Hospital, Catholic University of the Sacred Heart Roma
Italy Complesso Integrato Columbus Roma
Italy Policlinico Tor Vergata Roma
Italy Azienda Ospedaliera San Camillo Forlanini Rome
Italy A.S.O Ordine Mauriziano Di Torino Torino
Japan Fukuoka University Hospital Fukuoka
Japan Hamamatsu University Hospital Hamamatsu Shizuoka
Japan Kansai Medical University Hospital Hirakata Osaka
Japan Ofuna Chuo Hospital Kamakura-shi Kanagawa
Japan The jikei University Hospital Minato Tokyo
Japan Kyorin University Hospital Mitaka-City Tokyo
Japan Iwate Medical University - Uchimaru Medical Center Morioka Iwate
Japan Hyogo Medical University Hospital Nishinomiya-city Hyogo
Japan Saga University Hospital Saga
Japan Toho University Sakura Medical Center Sakura Chiba
Japan Sapporo Medical University Hospital Sapporo Hokkaido
Japan Tohoku University Hospital Sendai Miyagi
Japan Osaka Medical and Pharmaceutical University Hospital Takatsuki-shi Osaka
Japan Tokyo Medical and Dental University, Medical Hospital Tokyo
Japan Toyama University Hospital Toyama
Korea, Republic of Inje University Haeundae Paik Hospital Busan
Korea, Republic of Kosin University Gospel Hospital Busan
Korea, Republic of Keimyung University Dongsan Hospital Daegu
Korea, Republic of Asan Medical Center (AMC) Seoul
Korea, Republic of Asan Medical Center (AMC) Seoul
Korea, Republic of Chung-Ang University Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Korea, Republic of Yonsei University Wonju Severance Christian Hospital Wonju Gangwon
Netherlands Amsterdam University Medical Center (Amsterdam UMC), Academic Medical Center (AMC) Amsterdam
Netherlands Amsterdam University Medical Center (Amsterdam UMC), VU University Medical Center Amsterdam
Netherlands Onze Lieve Vrouwe Gasthuis (OLVG) - Locatie Oost Amsterdam
Netherlands Zuyderland Medisch Centrum - Sittard-Geleen Geleen Limburg
Netherlands St. Elisabeth Ziekenhuis Tilburg
Norway Vestre Viken HF - Baerum Sykehus Drammen Akershus
Norway Akershus University Hospital Lorenskog Akershus
Norway Oslo Univeristy Hospital Ulleval Hospital Oslo
Norway Oslo Universitetssykehus HF, Ulleval Oslo
Norway Universitetssykehuset Nord-Norge - Tromso (Regionsykehuset i Tromso) Tromso
Poland NZOZ Specjalistyczne Centrum Gastrologii GASTROMED Bialystok
Poland Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy Bydgoszcz Kujawsko-pomorskie
Poland Centrum Medyczne Pratia Gdynia Gdynia Pomorskie
Poland AmiCare Sp. z o.o. Sp. k. Lodz Lodzkie
Poland Centrum Medyczne Med-Gastr Lodz
Poland Oddzial Kliniczny Gastroenterologii Ogolnej i Onkologicznej SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Barlickiego Uniwersytetu Medycznego w Lodzi Lodz
Poland Medrise sp. z o.o Lublin
Poland Medicome Sp. z o.o. Oswiecim Malopolskie
Poland Centrum Medyczne Medyk Sp. z o.o. Sp. K. Rzeszow
Poland Korczowski Bartosz, Gabinet Lekarski Rzeszow
Poland Niepubliczny Zaklad Opieki Zdrowotnej Sonomed Szczecin Zachodniopomorskie
Poland Gastromed Kopon, Zmudzinski i Wspolnicy Sp.j. Specjalistyczne Centrum Gastrologii i Endoskopii Specjalistyczne Gabinety Lekarskie Torun Kujawsko-pomo
Poland H-T. Centrum Medyczne Sp. z o.o. Sp.k. Tychy
Poland WIP Warsaw IBD Point Profesor Kierkus, WIP Warsaw IBD Point Profesor Kierkus Warsaw
Poland Wojskowy Instytut Medyczny Warsaw
Poland Panstwowy Instytut Medyczny MSWiA Warszawa Mazowieckie
Poland Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Centrum Badan Klinicznych Osrodek Badan Wczesnej Fazy Wroclaw
Poland Centrum Medyczne Melita Medical Wroclaw Dolnoslaskie
Poland PlanetMed Sp. z o.o. Wroclaw Dolnoslaskie
Poland ETG Zamosc Zamosc
Romania Clinica Medicum Bucharest
Romania Clinical Hospital Colentina-Spitalul Clinic Colentina Bucharest
Romania Institutul Clinic Fundeni Bucuresti
Romania Policlinica Algomed: Centrul De Gastroenterologie Dr. Goldis Timisoara Jud Timis
Slovakia Fakultna nemocnica F. D. Roosevelta Banska Bystrica
Slovakia Cliniq s. r. o. Bratislava
Slovakia Endomed Kosice
Slovakia Fakultna Nemocnica s poliklinikou Nove Zamky Nove Zamky
Spain Hospital Universitario de Fuenlabrada Fuenlabrada
Spain Hospital Juan Ramon Jimenez Huelva
Spain Hospital Dr. Negrin Las Palmas De Gran Canaria
Spain Hospital General Universitario Gregorio Maranon (HGUGM) Madrid
Spain Hospital Universitario La Paz Madrid
Switzerland University Hospital Basel Basel
Switzerland Intesto - Gastroenterologische Praxis & Crohn-Colitis-Zentrum Bern Bern
Switzerland Intesto - Gastroenterologische Praxis & Crohn-Colitis-Zentrum Bern Bern
Switzerland University Hospital Bern (Inselspital) Bern
Switzerland Kantonsspital St. Gallen St. Gallen
Switzerland Universitatsspital Zurich Zurich
Taiwan Changhua Christian Hospital (CCH) Changhua City Changhua County
Taiwan Kaohsiung Medical University Hospital Kaohsiung
Taiwan China Medical University Hospital Taichung City
Taiwan National Taiwan University Hospital (NTUH) Taipei City Zhongzheng District
Taiwan Chang Gung Memorial Foundation Linkou Chang Gung Memorial Hospital Taoyuan City
United Kingdom South Eastern Health and Social Care Trust - The Ulster Hospital Belfast
United Kingdom South Eastern Health and Social Care Trust - The Ulster Hospital Belfast
United Kingdom Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust Cambridge Cambridgeshire
United Kingdom Spire Parkway Hospital, University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust Coventry West Midlands
United Kingdom St Mark's Hospital - North West London Hospitals Nhs Trust Harrow Middlesex
United Kingdom Clinical Research Centre - Barts Health NHS Trust London E1 2at
United Kingdom Clinical Research Centre - Barts Health NHS Trust London E1 2at
United Kingdom St George's University Hospitals NHS Foundation Trust London
United Kingdom St Thomas' Hospital - Guy's & St Thomas' NHS Foundation Trust London
United Kingdom Royal Victoria Infirmary - The Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle
United Kingdom Norfolk and Norwich University Hospital - Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich Norfolk
United States Emory University Hospital, The Emory Clinic Atlanta Georgia
United States Novel Research, LLC Bellaire Texas
United States Tidewater Gastroenterology, P.L.L.C. d/b/a Gastroenterology Associates of Tidewater Chesapeake Virginia
United States West Central Gastroenterology, LLP, d/b/a/ Gastro Florida Clearwater Florida
United States Baylor University Medical Center Dallas Texas
United States Atlanta Center For Gastroenterology, P.C. Decatur Georgia
United States Ohio Gastroenterology Group Dublin Ohio
United States THR Fort Worth Texas
United States VVCRD Clinical Research Garden Grove California
United States DHAT Research Institute Garland Texas
United States Woodholme Gastroenterology Associates Glen Burnie Maryland
United States Gastroenterology Associates, PA Greenville South Carolina
United States Victorium Clinical Research Houston Texas
United States Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics Iowa City Iowa
United States I.H.S Health, LLC Kissimmee Florida
United States Auzmer Research, Combined Research Orlando Phase I-IV Lakeland Florida
United States Las Vegas Medical Research Las Vegas Nevada
United States BVL Clinical Research Liberty Missouri
United States GastroIntestinal BioSciences Los Angeles California
United States University Of Louisville Louisville Kentucky
United States TDDC dba GI Alliance Research Mansfield Texas
United States Tandem Clinical Research GI, LLC Marrero Louisiana
United States Great Lakes Gastroenterology Research, LLC Mentor Ohio
United States Wellness Clinical Research Miami Lakes Florida
United States United Medical Doctors Murrieta California
United States GI PROS, Inc. Naples Florida
United States Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH) New York New York
United States Rochester Clinical Research New York New York
United States Weill Cornell Medical College of Cornell University New York New York
United States DiGiovanna Institute for Medical Education and Research North Massapequa New York
United States Hightower Clinical - SSM Health, Oklahoma University Health Sciences Center (OUHSC) Oklahoma City Oklahoma
United States UCI Health Orange California
United States Digestive Endoscopy Center NG-Gastroenterology Associates of Orangeburg Orangeburg South Carolina
United States University Gastroenterology Providence Rhode Island
United States Southern Star Research Institute, LLC San Antonio Texas
United States University of Washington Medical Center Seattle Washington
United States USF Tampa General Hospital Tampa Florida
United States DM Clinical Research Tomball Texas
United States Tyler Research Institute, LLC Tyler Texas
United States Victoria Gastroenterology Victoria Texas

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  China,  Czechia,  Denmark,  France,  Germany,  Greece,  Hungary,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Norway,  Poland,  Romania,  Slovakia,  Spain,  Switzerland,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Endoscopic Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12 Endoscopic response is defined by decrease in SES-CD >50% from baseline (or for participants with isolated ileal disease, SES-CD =4 or at least a 2-point reduction from baseline). SES-CD evaluates 4 endoscopic variables (the intestinal surface affected by ulcers, the intestinal surface affected by other inflammatory lesions, the presence of ulcers, and the presence of narrowing). Week 12
Secondary Percentage of Participants Achieving Clinical Remission Based on the Crohn's Disease Activity Index (CDAI) at Week 12 Clinical remission is defined as a CDAI score of <150 points. Week 12
Secondary Percentage of Participants With a Clinical Response Based on the CDAI at Week 12 Clinical response is defined as =100-point decrease from Baseline in CDAI score. Week 12
Secondary Percentage of Participants Achieving Endoscopic Remission Based on SES-CD at Week 12. Endoscopic remission as per SES-CD is defined as SES-CD score =4 or =2 for ileal disease, no subscore >1. Week 12
Secondary Percentage of Participants Achieving Clinical Remission in 2-item Patient-reported Outcome Measure (PRO2) at Week 12 Clinical remission based on PRO2 is defined as average daily liquid or very soft stool frequency (SF) score =2.8 and not worse than baseline and average daily abdominal pain (AP) score =1 and not worse than baseline. Week 12
Secondary Percentage of Participants With a Clinical Response in PRO2 at Week 12 Clinical response based on PRO2 is defined as =30% decrease in average daily very soft or liquid stools and/ or =30% decrease in average AP from baseline. Week 12
Secondary Percentage of Participants With no Bowel Urgency at Week 12 Bowel urgency is assessed using a 1-item daily patient diary that asks participants to indicate if they had an urgent bowel movement (when they felt the need to rush to the toilet to avoid an accident) in the past 24 hours. Response options, "Yes" or "No" will be coded as numeric values. Week 12
Secondary Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score =170 at Week 12 The IBDQ is a 32-item questionnaire that measures 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. Within dimensions, each question will be assessed on a 7-point Likert scale. Each domain score is the sum of 8 responses each ranging from 1 to 7, where 1 indicates worst function and 7 the best. The total score ranges from 32 to 224, with higher scores representing better quality of life. Week 12
Secondary Change from Baseline in Health-related Quality of Life (HRQoL) as per IBDQ Total Score at Week 12 The IBDQ is a 32-item questionnaire that measures 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. Within dimensions, each question will be assessed on a 7-point Likert scale. Each domain score is the sum of 8 responses each ranging from 1 to 7, where 1 indicates worst function and 7 the best. The total score ranges from 32 to 224, with higher scores representing better quality of life. Baseline to Week 12
Secondary Change from Baseline in Fatigue as per Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 12 FACIT-Fatigue questionnaire contains 13 fatigue-related questions. The responses to the 13 items on the FACIT-Fatigue questionnaire are each measured on a 5-point Likert scale, where 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit and 4=Very much. The total score ranges from 0 to 52. High scores represent less fatigue. Baseline to Week 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01951326 - Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Phase 3